Servier has extended its partnership with Google Cloud, highlighting 60 ways generative AI can enhance drug development. Initially signed in 2022, the collaboration aimed to establish a strong technological framework for data security and AI initiatives. The extension will integrate Google Cloud's AI solutions throughout Servier's entire value chain.
The partnership will enable Servier to utilize generative AI for various applications, including identifying therapeutic targets and digitizing clinical trials. Employees will receive tools based on Google Cloud's AI technology, such as the Gemini large language models. This collaboration is expected to drive significant advancements in disease research and treatment.
• Servier identifies 60 AI use cases to enhance drug development.
• Google Cloud's AI technology will be integrated across Servier's operations.
In this context, it is used by Servier to accelerate drug development processes.
Servier is providing its employees with tools based on Google Cloud's Gemini large language models.
Google Cloud provides AI solutions that enhance data processing and analytics for various industries, including biopharma.
Servier is a French biopharmaceutical company leveraging AI to improve its drug development processes.
TechCrunch on MSN.com 11month
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.